Have any questions? 706-721-6582 or cts@augusta.edu
- PRT543-01: A Phase I, Open-Label, Multicenter, Dose Escalation, Dose Expansion Study of PRT543 in Patients with Advanced Solid Tumors and Hematologic Malignancies
Clinical Trial
PRT543-01: A Phase I, Open-Label, Multicenter, Dose Escalation, Dose Expansion Study of PRT543 in Patients with Advanced Solid Tumors and Hematologic Malignancies
This research study involves receiving a study drug referred to as PRT543. This study is a Phase 1 study and this is the first study in humans using the study drug. You are being invited to participate in either dose escalation or dose expansion depending on which portion of the study is open when you join. The purpose of dose escalation is to test the safety of the study drug, at different dose levels and to find out what effects, good and/or bad, the study drug has on you and your type of cancer. The information collected from you and from other patients in the study when taking different dose levels will be used to decide the most appropriate dose of the study drug that should be used in dose expansion and for other studies which may be completed in the future.
Eligibility Criteria
- Male or female, aged 18 years or older Must have malignancies that are refractory to established therapies known to provide clinical benefit for the malignancy in question, be intolerant of established therapies known to provide clinical benefit for the malignancy in question, or in the opinion of the Investigator, not be a candidate for such therapies. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures